- Home
- ECO vs SYRE Comparison
ECO vs SYRE Comparison
Compare ECO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- SYRE
- Stock Information
- Founded
- ECO 2018
- SYRE 2013
- Country
- ECO Greece
- SYRE United States
- Employees
- ECO N/A
- SYRE N/A
- Industry
- ECO
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- SYRE Health Care
- Exchange
- ECO Nasdaq
- SYRE Nasdaq
- Market Cap
- ECO 1.0B
- SYRE 1.1B
- IPO Year
- ECO N/A
- SYRE 2016
- Fundamental
- Price
- ECO $38.31
- SYRE $23.71
- Analyst Decision
- ECO Strong Buy
- SYRE Strong Buy
- Analyst Count
- ECO 2
- SYRE 5
- Target Price
- ECO $37.00
- SYRE $55.75
- AVG Volume (30 Days)
- ECO 231.4K
- SYRE 741.8K
- Earning Date
- ECO 11-12-2025
- SYRE 11-04-2025
- Dividend Yield
- ECO 5.52%
- SYRE N/A
- EPS Growth
- ECO N/A
- SYRE N/A
- EPS
- ECO 2.38
- SYRE N/A
- Revenue
- ECO $349,886,578.00
- SYRE N/A
- Revenue This Year
- ECO N/A
- SYRE N/A
- Revenue Next Year
- ECO $21.20
- SYRE N/A
- P/E Ratio
- ECO $15.92
- SYRE N/A
- Revenue Growth
- ECO N/A
- SYRE N/A
- 52 Week Low
- ECO $17.91
- SYRE $10.91
- 52 Week High
- ECO $39.77
- SYRE $33.47
- Technical
- Relative Strength Index (RSI)
- ECO 73.43
- SYRE 60.31
- Support Level
- ECO $32.86
- SYRE $21.63
- Resistance Level
- ECO $39.77
- SYRE $24.19
- Average True Range (ATR)
- ECO 0.92
- SYRE 1.33
- MACD
- ECO 0.37
- SYRE -0.26
- Stochastic Oscillator
- ECO 81.07
- SYRE 67.01
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.